Australia markets open in 4 hours 31 minutes

Evoke Pharma, Inc. (EV00.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
4.1800+0.2600 (+6.63%)
At close: 03:39PM CET

Evoke Pharma, Inc.

420 Stevens Avenue
Suite 370
Solana Beach, CA 92075
United States
858 345 1494

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. David A. GonyerCo-Founder, CEO, Pres & Director737.24kN/A1964
Mr. Matthew J. D'OnofrioCo-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec.524.45kN/A1970
Dr. Marilyn R. CarlsonChief Medical Officer491.69kN/A1948
Mr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Corporate governance

Evoke Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.